230 related articles for article (PubMed ID: 27749739)
21. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study.
Shumaker SA; Legault C; Kuller L; Rapp SR; Thal L; Lane DS; Fillit H; Stefanick ML; Hendrix SL; Lewis CE; Masaki K; Coker LH;
JAMA; 2004 Jun; 291(24):2947-58. PubMed ID: 15213206
[TBL] [Abstract][Full Text] [Related]
22. Hormone therapy dose, formulation, route of delivery, and risk of cardiovascular events in women: findings from the Women's Health Initiative Observational Study.
Shufelt CL; Merz CN; Prentice RL; Pettinger MB; Rossouw JE; Aroda VR; Kaunitz AM; Lakshminarayan K; Martin LW; Phillips LS; Manson JE
Menopause; 2014 Mar; 21(3):260-6. PubMed ID: 24045672
[TBL] [Abstract][Full Text] [Related]
23. Randomized Trial Evaluation of the Benefits and Risks of Menopausal Hormone Therapy Among Women 50-59 Years of Age.
Prentice RL; Aragaki AK; Chlebowski RT; Rossouw JE; Anderson GL; Stefanick ML; Wactawski-Wende J; Kuller LH; Wallace R; Johnson KC; Shadyab AH; Gass M; Manson JE
Am J Epidemiol; 2021 Feb; 190(3):365-375. PubMed ID: 33025002
[TBL] [Abstract][Full Text] [Related]
24. Conjugated equine estrogens and colorectal cancer incidence and survival: the Women's Health Initiative randomized clinical trial.
Ritenbaugh C; Stanford JL; Wu L; Shikany JM; Schoen RE; Stefanick ML; Taylor V; Garland C; Frank G; Lane D; Mason E; McNeeley SG; Ascensao J; Chlebowski RT;
Cancer Epidemiol Biomarkers Prev; 2008 Oct; 17(10):2609-18. PubMed ID: 18829444
[TBL] [Abstract][Full Text] [Related]
25. Estrogen alone in postmenopausal women and breast cancer detection by means of mammography and breast biopsy.
Chlebowski RT; Anderson G; Manson JE; Pettinger M; Yasmeen S; Lane D; Langer RD; Hubbell FA; McTiernan A; Hendrix S; Schenken R; Stefanick ML
J Clin Oncol; 2010 Jun; 28(16):2690-7. PubMed ID: 20439627
[TBL] [Abstract][Full Text] [Related]
26. Postmenopausal hormone use and the risk of nephrolithiasis: results from the Women's Health Initiative hormone therapy trials.
Maalouf NM; Sato AH; Welch BJ; Howard BV; Cochrane BB; Sakhaee K; Robbins JA
Arch Intern Med; 2010 Oct; 170(18):1678-85. PubMed ID: 20937929
[TBL] [Abstract][Full Text] [Related]
27. Comparison of clinical outcomes among users of oral and transdermal estrogen therapy in the Women's Health Initiative Observational Study.
Crandall CJ; Hovey KM; Andrews C; Cauley JA; Stefanick M; Shufelt C; Prentice RL; Kaunitz AM; Eaton C; Wactawski-Wende J; Manson JE
Menopause; 2017 Oct; 24(10):1145-1153. PubMed ID: 28697036
[TBL] [Abstract][Full Text] [Related]
28. Estrogen-plus-progestin use and mammographic density in postmenopausal women: Women's Health Initiative randomized trial.
McTiernan A; Martin CF; Peck JD; Aragaki AK; Chlebowski RT; Pisano ED; Wang CY; Brunner RL; Johnson KC; Manson JE; Lewis CE; Kotchen JM; Hulka BS;
J Natl Cancer Inst; 2005 Sep; 97(18):1366-76. PubMed ID: 16174858
[TBL] [Abstract][Full Text] [Related]
29. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial.
Chlebowski RT; Hendrix SL; Langer RD; Stefanick ML; Gass M; Lane D; Rodabough RJ; Gilligan MA; Cyr MG; Thomson CA; Khandekar J; Petrovitch H; McTiernan A;
JAMA; 2003 Jun; 289(24):3243-53. PubMed ID: 12824205
[TBL] [Abstract][Full Text] [Related]
30. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial.
Cauley JA; Robbins J; Chen Z; Cummings SR; Jackson RD; LaCroix AZ; LeBoff M; Lewis CE; McGowan J; Neuner J; Pettinger M; Stefanick ML; Wactawski-Wende J; Watts NB;
JAMA; 2003 Oct; 290(13):1729-38. PubMed ID: 14519707
[TBL] [Abstract][Full Text] [Related]
31. Estrogen plus progestin and breast cancer incidence and mortality in the Women's Health Initiative Observational Study.
Chlebowski RT; Manson JE; Anderson GL; Cauley JA; Aragaki AK; Stefanick ML; Lane DS; Johnson KC; Wactawski-Wende J; Chen C; Qi L; Yasmeen S; Newcomb PA; Prentice RL
J Natl Cancer Inst; 2013 Apr; 105(8):526-35. PubMed ID: 23543779
[TBL] [Abstract][Full Text] [Related]
32. Effects of conjugated equine estrogen on risk of fractures and BMD in postmenopausal women with hysterectomy: results from the women's health initiative randomized trial.
Jackson RD; Wactawski-Wende J; LaCroix AZ; Pettinger M; Yood RA; Watts NB; Robbins JA; Lewis CE; Beresford SA; Ko MG; Naughton MJ; Satterfield S; Bassford T;
J Bone Miner Res; 2006 Jun; 21(6):817-28. PubMed ID: 16753012
[TBL] [Abstract][Full Text] [Related]
33. Women's Health Initiative clinical trials: potential interactive effect of calcium and vitamin D supplementation with hormonal therapy on cardiovascular disease.
Jiang X; Nudy M; Aragaki AK; Robbins JA; Manson JE; Stefanick ML; OʼSullivan DM; Shikany JM; LeBlanc ES; Kelsey AM; Cauley J; Martin LW; Payne ME; Johnson KC; Howard B; Schnatz PF
Menopause; 2019 Aug; 26(8):841-849. PubMed ID: 31145202
[TBL] [Abstract][Full Text] [Related]
34. Menopausal hormone therapy and risks of melanoma and nonmelanoma skin cancers: women's health initiative randomized trials.
Tang JY; Spaunhurst KM; Chlebowski RT; Wactawski-Wende J; Keiser E; Thomas F; Anderson ML; Zeitouni NC; Larson JC; Stefanick ML
J Natl Cancer Inst; 2011 Oct; 103(19):1469-75. PubMed ID: 21878677
[TBL] [Abstract][Full Text] [Related]
35. Estrogen therapy and breast cancer in randomized clinical trials: a narrative review.
Pan K; Lavasani S; Aragaki AK; Chlebowski RT
Menopause; 2022 Sep; 29(9):1086-1092. PubMed ID: 35969882
[TBL] [Abstract][Full Text] [Related]
36. Coronary heart disease events in the Women's Health Initiative hormone trials: effect modification by metabolic syndrome: a nested case-control study within the Women's Health Initiative randomized clinical trials.
Wild RA; Wu C; Curb JD; Martin LW; Phillips L; Stefanick M; Trevisan M; Manson JE
Menopause; 2013 Mar; 20(3):254-60. PubMed ID: 23435021
[TBL] [Abstract][Full Text] [Related]
37. Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin.
Heiss G; Wallace R; Anderson GL; Aragaki A; Beresford SA; Brzyski R; Chlebowski RT; Gass M; LaCroix A; Manson JE; Prentice RL; Rossouw J; Stefanick ML;
JAMA; 2008 Mar; 299(9):1036-45. PubMed ID: 18319414
[TBL] [Abstract][Full Text] [Related]
38. Postmenopausal Female Hormone Use and Estrogen Receptor-Positive and -Negative Breast Cancer in African American Women.
Rosenberg L; Bethea TN; Viscidi E; Hong CC; Troester MA; Bandera EV; Haiman CA; Kolonel LN; Olshan AF; Ambrosone CB; Palmer JR
J Natl Cancer Inst; 2016 Apr; 108(4):. PubMed ID: 26613937
[TBL] [Abstract][Full Text] [Related]
39. Effects of oral conjugated equine estrogens with or without medroxyprogesterone acetate on incident hypertension in the Women's Health Initiative hormone therapy trials.
Swica Y; Warren MP; Manson JE; Aragaki AK; Bassuk SS; Shimbo D; Kaunitz A; Rossouw J; Stefanick ML; Womack CR
Menopause; 2018 Jul; 25(7):753-761. PubMed ID: 29381666
[TBL] [Abstract][Full Text] [Related]
40. Estrogen and colorectal cancer incidence and mortality.
Lavasani S; Chlebowski RT; Prentice RL; Kato I; Wactawski-Wende J; Johnson KC; Young A; Rodabough R; Hubbell FA; Mahinbakht A; Simon MS
Cancer; 2015 Sep; 121(18):3261-71. PubMed ID: 26036212
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
